ARDC Research Link Australia Research Link Australia   BETA Research
Link
Australia
  • ARDC Newsletter Subscribe
  • Contact Us
  • Home
  • About
  • Feedback
  • Explore Collaborations
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation

Need help searching? View our Search Guide.

Advanced Search

Current Selection
Field of Research : Infectious Agents
Field of Research : Diagnostic Applications
Clear All
Filter by Field of Research
Diagnostic Applications (4)
Infectious Agents (4)
Microbiology (3)
Virology (2)
Agricultural Biotechnology (1)
Microbiology Not Elsewhere Classified (1)
Transgenesis (1)
Filter by Socio-Economic Objective
Infectious diseases (2)
Diagnostics (1)
Disease distribution and transmission (1)
Forestry (1)
Native forests (1)
Ornamentals, Australian natives and nursery plants (1)
Rural health (1)
Filter by Funding Provider
Australian Research Council (4)
Filter by Status
Closed (4)
Filter by Scheme
Linkage Projects (4)
Filter by Country
Australia (4)
Filter by Australian State/Territory
NSW (2)
QLD (1)
SA (1)
  • Researchers (11)
  • Funded Activities (4)
  • Organisations (13)
  • Funded Activity

    Linkage Projects - Grant ID: LP0211022

    Funder
    Australian Research Council
    Funding Amount
    $194,344.00
    Summary
    Production and application of novel diagnostic and therapeutic reagents using transgenic mice. The project will be a collaboration between the University of Queensland and PanBio Ltd. We intend to use humanized transgenic mice to produce fully human monoclonal antibodies. Fully human antibodies have great advantages over murine antibodies as diagnostics and therapeutics. These reagents will be used to 1)replace human sera , 2)replace antigens from infectious organisms in a range of diagnostic .... Production and application of novel diagnostic and therapeutic reagents using transgenic mice. The project will be a collaboration between the University of Queensland and PanBio Ltd. We intend to use humanized transgenic mice to produce fully human monoclonal antibodies. Fully human antibodies have great advantages over murine antibodies as diagnostics and therapeutics. These reagents will be used to 1)replace human sera , 2)replace antigens from infectious organisms in a range of diagnostic kits for animal and human infectious disease and 3) as therapeutic leads and 4)to discover vaccine leads. The project will allow production of diagnostic kits where this was previously not feasible or not economically viable (eg. uncommon and/or dangerous animal or human diseases) and will lead to development of novel infectious disease diagnostics and therapeutics.
    Read more Read less
    More information
    Funded Activity

    Linkage Projects - Grant ID: LP0454036

    Funder
    Australian Research Council
    Funding Amount
    $180,000.00
    Summary
    A comparative study of the distribution and spread of potential molecular markers for Mundulla Yellows disease. Mundulla Yellows (MY), a newly recognised widespread lethal disease of Eucalyptus spp.in Australia, is a serious threat to national biodiversity and conservation. It is contagious, apparently biotic, but the causal agent is unknown. Identification of the cause is essential to establish sustainable control measures. We have detected a range of MY-associated RNAs constituting a disease ' .... A comparative study of the distribution and spread of potential molecular markers for Mundulla Yellows disease. Mundulla Yellows (MY), a newly recognised widespread lethal disease of Eucalyptus spp.in Australia, is a serious threat to national biodiversity and conservation. It is contagious, apparently biotic, but the causal agent is unknown. Identification of the cause is essential to establish sustainable control measures. We have detected a range of MY-associated RNAs constituting a disease 'fingerprint'. To identify individual RNAs uniquely associated with MY we aim to compare MY-RNA fingerprints from a range of affected species from different sites and with varying symptoms. Candidate RNAs will be cloned both for establishing molecular diagnostics for MY and identifying the cause.
    Read more Read less
    More information
    Funded Activity

    Linkage Projects - Grant ID: LP0210513

    Funder
    Australian Research Council
    Funding Amount
    $146,203.00
    Summary
    Development of SELEX technology (Systematic Evolution of Ligands by EXponential enrichment). A recently developed in vitro genetic selection technique has allowed the isolation of oligonucleotides that can bind target molecules with high affinity and specificity. The strategy know as SELEX (Systematic Evolution of Ligands by EXponential enrichment) uses protein biochemistry and PCR technology, with subsequent repeated rounds of selection and amplification, to screen vast libraries of oligonucle .... Development of SELEX technology (Systematic Evolution of Ligands by EXponential enrichment). A recently developed in vitro genetic selection technique has allowed the isolation of oligonucleotides that can bind target molecules with high affinity and specificity. The strategy know as SELEX (Systematic Evolution of Ligands by EXponential enrichment) uses protein biochemistry and PCR technology, with subsequent repeated rounds of selection and amplification, to screen vast libraries of oligonucleotides (RNA or DNA) for their ability to bind target proteins. This procedure will be developed by UNSW in collaboration with the biotech company BTF Plc., Ltd., to be used in two applications. The first is the research interest of UNSW and involves the development of aptamers against hepatitis C virus. The second lies within the interests of BTF and will involve the development of aptamers against the water borne pathogen Cryptosporidium parvum.
    Read more Read less
    More information
    Funded Activity

    Linkage Projects - Grant ID: LP0219771

    Funder
    Australian Research Council
    Funding Amount
    $250,938.00
    Summary
    Antigenic analysis of the surface of Cyclospora cayetanensis oocysts. Infection with Cyclospora cayetanensis is an emerging disease that causes significant morbidity in human populations. Although prevalent in developing countries, recent outbreaks in the USA confirm it is now emerging into the developed world. The research described here will analyse and characterise the antigens on the surface of the oocyst of C. cayetanensis which will add significantly to our sparse knowledge on this impor .... Antigenic analysis of the surface of Cyclospora cayetanensis oocysts. Infection with Cyclospora cayetanensis is an emerging disease that causes significant morbidity in human populations. Although prevalent in developing countries, recent outbreaks in the USA confirm it is now emerging into the developed world. The research described here will analyse and characterise the antigens on the surface of the oocyst of C. cayetanensis which will add significantly to our sparse knowledge on this important human parasite. We will also develop the first commercial antibodies and technologies which will rapidly and accurately detect the parasite in human patients and our drinking water supplies, thus securing a global market for Australian technology.
    Read more Read less
    More information

    Showing 1-4 of 4 Funded Activites

    Advanced Search

    Advanced search on the Researcher index.

    Advanced search on the Funded Activity index.

    Advanced search on the Organisation index.

    National Collaborative Research Infrastructure Strategy

    The Australian Research Data Commons is enabled by NCRIS.

    ARDC CONNECT NEWSLETTER

    Subscribe to the ARDC Connect Newsletter to keep up-to-date with the latest digital research news, events, resources, career opportunities and more.

    Subscribe

    Quick Links

    • Home
    • About Research Link Australia
    • Product Roadmap
    • Documentation
    • Disclaimer
    • Contact ARDC

    We acknowledge and celebrate the First Australians on whose traditional lands we live and work, and we pay our respects to Elders past, present and emerging.

    Copyright © ARDC. ACN 633 798 857 Terms and Conditions Privacy Policy Accessibility Statement
    Top
    Quick Feedback